MEAGAN ADAMSICK, PHARMD*

Articles by MEAGAN ADAMSICK, PHARMD*

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy

ByMEAGAN ADAMSICK, PHARMD*

December 20th 2020

The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions

ByMEAGAN ADAMSICK, PHARMD*,MONIQUE R. BIDELL, PHARMD, BCPS

February 11th 2020

Readmission rates for patients receiving OPAT are reported to be as high as 20%, mostly due to catheter-related problems, adverse drug reactions, or worsening of the primary infection.

Latest Updated Articles

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy
December 20th 2020
The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions
February 11th 2020

MEAGAN ADAMSICK, PHARMD*

Articles by MEAGAN ADAMSICK, PHARMD*

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy

The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions

Latest Updated Articles

Trending on Contagion Live

SNAP Global Trial Supports Cefazolin for MSSA Bacteremia

Important Clinical Practice Takeaways From the DOTs and PeterPen Trials

10 Infectious Disease Developments That Defined Q2 2026

FDA Grants Priority Review for Dolutegravir in Newborns With HIV

Merck, ADAP Crisis Task Force Agree to Expand IDVYNSO Access in HIV